Svensson, F;
Zanders, ED;
Bailey, DS;
(2019)
Therapy for glioblastoma: is it working?
[Review].
Drug Discovery Today
, 24
(5)
pp. 1193-1201.
10.1016/j.drudis.2019.03.008.
Preview |
Text
Svensson_1-s2.0-S1359644618301880-main.pdf - Published Version Download (464kB) | Preview |
Abstract
Glioblastoma (GBM) remains one of the most intransigent of cancers, with a median overall survival of only 15 months after diagnosis. Drug treatments have largely proven ineffective, due, it is thought, to the heterogeneous nature and plasticity of GBM-initiating stem cell lineages. While many combination drug therapies are being positioned to address tumour heterogeneity, the most promising therapeutic approaches for GBM to date appear to be those targeting GBM by vaccination or antibody- and cell-based immunotherapy. We review the most recent clinical trials for GBM and discuss the role of adaptive clinical trials in developing personalised treatment strategies to address both intra- and inter-tumoral heterogeneity.
Archive Staff Only
 |
View Item |
